Glucagon-Like Peptide-2 as a Potential Biomarker for Nonalcoholic Fatty Liver Disease in Children with Obesity: Preliminary Assessment of Metabolic Associations and Underlying Mechanisms.
{"title":"Glucagon-Like Peptide-2 as a Potential Biomarker for Nonalcoholic Fatty Liver Disease in Children with Obesity: Preliminary Assessment of Metabolic Associations and Underlying Mechanisms.","authors":"Shu-Juan Zhang, Ke Xu, Feng Zhu, Yi-Qun Teng, Yan-Fei Tang, Hong-Wei Xu","doi":"10.2147/DMSO.S528780","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effects of glucagon-like peptide-2 (GLP-2) on insulin resistance and lipid metabolism, as well as potential mechanisms contributing to the development of non-alcoholic fatty liver disease (NAFLD) in children with obesity.</p><p><strong>Methods: </strong>A cross-sectional study was conducted involving 107 children with obesity, aged between 5 and 15 years, including 55 with NAFLD and 52 without NAFLD. Anthropometric assessments and fasting blood samples were collected to evaluate GLP-2, plasma glucose, insulin (INS), lipids, leptin (LEP), and adiponectin (ADPN). Correlation and logistic regression analyses were performed to evaluate associations between GLP-2 and metabolic parameters.</p><p><strong>Results: </strong>Children with NAFLD exhibited significantly higher levels of GLP-2, LEP, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FPG), INS, and the homeostasis model assessment of insulin resistance index (HOMA-IR) (all <i>p</i><0.05), along with significantly lower levels of ADPN and high-density lipoprotein cholesterol (HDL-C) compared with those without NAFLD (<i>p</i><0.05). GLP-2 concentrations correlated positively with TC (<i>r</i>=0.42), TG (<i>r</i>=0.51), LDL-C (<i>r</i>=0.38), FPG (<i>r</i>=0.61), INS (<i>r</i>=0.58), HOMA-IR (<i>r</i>=0.61), and LEP (<i>r</i>=0.42), and negatively with ADPN (<i>r</i>=-0.53; all <i>p</i><0.01). In univariate analysis, GLP-2 was identified as a risk factor for NAFLD (odds ratio [OR]=1.225, 95% confidence interval [CI]: 1.001-1.499, <i>p</i><0.05); however, the association was attenuated after adjustment for body mass index (OR=1.112, <i>p</i>=0.102). ADPN retained a protective association (OR=0.771, <i>p</i><0.05).</p><p><strong>Conclusion: </strong>GLP-2 may contribute to the pathophysiology of insulin resistance and dyslipidemia in pediatric NAFLD, potentially via modulation of adipokine activity. These findings suggest GLP-2 as a candidate biomarker and possible therapeutic target in this population.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3515-3525"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452961/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S528780","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to investigate the effects of glucagon-like peptide-2 (GLP-2) on insulin resistance and lipid metabolism, as well as potential mechanisms contributing to the development of non-alcoholic fatty liver disease (NAFLD) in children with obesity.
Methods: A cross-sectional study was conducted involving 107 children with obesity, aged between 5 and 15 years, including 55 with NAFLD and 52 without NAFLD. Anthropometric assessments and fasting blood samples were collected to evaluate GLP-2, plasma glucose, insulin (INS), lipids, leptin (LEP), and adiponectin (ADPN). Correlation and logistic regression analyses were performed to evaluate associations between GLP-2 and metabolic parameters.
Results: Children with NAFLD exhibited significantly higher levels of GLP-2, LEP, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FPG), INS, and the homeostasis model assessment of insulin resistance index (HOMA-IR) (all p<0.05), along with significantly lower levels of ADPN and high-density lipoprotein cholesterol (HDL-C) compared with those without NAFLD (p<0.05). GLP-2 concentrations correlated positively with TC (r=0.42), TG (r=0.51), LDL-C (r=0.38), FPG (r=0.61), INS (r=0.58), HOMA-IR (r=0.61), and LEP (r=0.42), and negatively with ADPN (r=-0.53; all p<0.01). In univariate analysis, GLP-2 was identified as a risk factor for NAFLD (odds ratio [OR]=1.225, 95% confidence interval [CI]: 1.001-1.499, p<0.05); however, the association was attenuated after adjustment for body mass index (OR=1.112, p=0.102). ADPN retained a protective association (OR=0.771, p<0.05).
Conclusion: GLP-2 may contribute to the pathophysiology of insulin resistance and dyslipidemia in pediatric NAFLD, potentially via modulation of adipokine activity. These findings suggest GLP-2 as a candidate biomarker and possible therapeutic target in this population.
期刊介绍：
An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
